Description

Glipizide Extended-Release Tablets 5mg (CR Double-Crane) are formulated for controlled-release and primarily used in diabetes-related experimental studies. This sulfonylurea derivative is commonly employed in academic and preclinical settings to investigate glucose-lowering pharmacology, pancreatic beta-cell insulin secretion, and glycemic control mechanisms in type 2 diabetes.

Manufactured by China Resources Double-Crane Pharmaceutical (Jinan) Co., Ltd., these tablets are provided for research and laboratory use only, not for clinical or human consumption.

Glipizide Extended-Release Product Parameters

Glipizide Extended-Release Mechanism & Research Applications

Glipizide functions by stimulating insulin release from pancreatic beta cells by closing ATP-sensitive potassium channels. The extended-release formulation offers a prolonged therapeutic profile, making it ideal for simulating once-daily dosing regimens in experimental diabetes models.

Research uses include:

• Studies on sustained insulin secretion dynamics

• In vivo blood glucose regulation modeling

• Sulfonylurea pharmacokinetics and bioavailability testing

• Comparative studies of controlled vs. immediate-release forms

Observed Effects in Research

• Prolonged plasma insulin levels in animal models

• Reduction in fasting and postprandial glucose levels

• Extended action curve vs. IR glipizide

• Beta-cell response modulation under chronic dosing

Safety & Handling

• For laboratory research only

• Not intended for human or veterinary use

• Store in a cool, dry place away from light

• Use personal protective equipment when handling

• Dispose of according to local research waste protocols

Research Use Disclaimer

This product is intended for laboratory and research use only. It is not for human use. Use must comply with local research and safety regulations.